How do AQP4 and GFAP antibodies differ in their effects on astrocytes?

The claim accurately distinguishes two forms of astrocyte-directed immune reactivity with importantly different biological implications. AQP4-IgG has direct pathogenic evidence in neuromyelitis optica spectrum disorder (NMOSD), whereas GFAP-IgG is most informative as a biomarker of immune reactivity to an intracellular astrocytic protein.

AQP4-IgG mechanism and clinical relevance

• AQP4-IgG binds extracellular aquaporin-4 water channels on astrocyte surfaces, particularly AQP4 organized in orthogonal arrays. This clustering enables multivalent C1q binding and activation of the classical complement pathway.
• In cellular models, AQP4-IgG plus complement produces C9neo/C5b-9 membrane-attack-complex deposition and astrocyte cytotoxicity. Human NMOSD lesions likewise contain complement/MAC deposition associated with astrocytic pathology.
• In vivo, prominent C5b-9 deposition in brain, spinal cord, and optic nerve precedes astrocyte loss and inflammation, supporting complement activation as an initiating injury mechanism rather than solely a consequence of tissue destruction.
• Complement is a major, but not exclusive, pathway: antibody-dependent cellular cytotoxicity may also contribute. Serum AQP4-IgG cell-based assays are the clinically validated testing approach, interpreted in the context of a compatible phenotype.

GFAP-IgG interpretation

• GFAP-IgG identifies immune reactivity against glial fibrillary acidic protein, an intracellular intermediate-filament protein of astrocytes. It does not imply an unidentified “second” target beyond GFAP itself.
• Antigen-confirmed CSF GFAPα-IgG is more diagnostically persuasive than serum-only positivity. Tissue-based assays combined with GFAPα-transfected cell-based confirmation improve specificity.
• Because GFAP is intracellular, direct antibody-mediated injury is less compelling biologically; T-cell-mediated mechanisms are proposed contributors. Isolated GFAP-IgM does not establish GFAP astrocytopathy.

Bottom line

• AQP4-IgG can directly bind astrocytic AQP4 and drive classical-complement/MAC-mediated injury; confirmed GFAP-IgG identifies immune reactivity to the distinct astrocytic protein GFAP, primarily as a disease-associated biomarker rather than established direct pathogenic antibody.